Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Recruiting
Phase 1
Interventional Study
Hepatocellular Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 20 – 60
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3 (estimated)
- Sponsor
- Dr Cipto Mangunkusumo General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study represents a phase I clinical trial that utilizes natural killer (NK) cell therapy for patients diagnosed with liver cancer, specifically those classified as Child-Pugh A and falling within the Barcelona Clinic Liver Cancer (BCLC) stages B or C. The expected results include determining the suitable treatment dosage, identifying any resulting side effects, and calculating the average dur…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 20-60 years old
* Patients with Hepatocellular Carcinoma (HCC) staged as BCLC B and C
* Karnofsky Performance Status (KPS) score ≥ 70
* Expected patient survival of more than three months
* The following parameters are within the normal range:
Platelet count ≥ 8…
Contacts